STEGLUJAN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania.

Active ingredients

The drug STEGLUJAN contains a combination of these active pharmaceutical ingredients (APIs):

1	Ertugliflozin UNII MLU731K321 - ERTUGLIFLOZIN PIDOLATE
	Ertugliflozin helps to lower blood glucose by making the patient pass out glucose in the urine. It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.
	Read more about Ertugliflozin
2	Sitagliptin UNII TS63EW8X6F - SITAGLIPTIN PHOSPHATE
	Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones.
	Read more about Sitagliptin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STEGLUJAN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BD23	Metformin and ertugliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD23
A10BD24		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11561L, 11578J, 11579K, 11583P
EE	Ravimiamet	1767988, 1767999, 1768002, 1768013, 1768024, 1768035, 1768046, 1768057, 1768068, 1768079, 1778878, 1778889
FI	Lääkealan turvallisuus- ja kehittämiskeskus	071784, 159405, 416330, 502790
FR	Base de données publique des médicaments	64446015, 66301278
HK	Department of Health Drug Office	66205, 66206
IE	Health Products Regulatory Authority	43770, 43771
IL	מִשְׂרַד הַבְּרִיאוּת	8541, 8542
IT	Agenzia del Farmaco	046342010, 046342022, 046342034, 046342046, 046342059, 046342073, 046342085, 046342097, 046342109, 046342111, 046342123, 046342147
LT	Valstybinė vaistų kontrolės tarnyba	1085324, 1085325, 1085326, 1085327, 1085328, 1085329, 1085330, 1085331, 1085332, 1085333, 1085334, 1085335, 1085742, 1085743
NL	Z-Index G-Standaard, PRK	167681, 167703
PL	Rejestru Produktów Leczniczych	100404697, 100404705
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66527001, W66527002, W66527003, W66528001, W66528002, W66528003, W66528004
US	FDA, National Drug Code	0006-5367, 0006-5368